BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioCardia, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.5525 (−38.10%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BioCardia, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$7.57M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$7.39M
TTM Q2 2026
Free cash flow
-$7.57M
TTM Q2 2026
EPS, diluted
-$0.77
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $10.85M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.02
- Dividend yield
- –
- Free cash flow yield
- -69.76%
Fundamentals
- Revenue
- $0
- Net income
- -$7.34M
- EPS, diluted
- -$0.77
- Free cash flow
- -$7.57M
- Book value per share
- $0.22
- Diluted shares
- 12M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$7.39M
Net income
-$7.34M
EPS, diluted
-$0.77
Free cash flow
-$7.57M
Reported periodTrailing twelve months